Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors. / Erikstrup, Christian; Hother, Christoffer Egeberg; Pedersen, Ole Birger Vestager; Mølbak, Kåre; Skov, Robert Leo; Holm, Dorte Kinggaard; Saekmose, Susanne Gjorup; Nilsson, Anna Christine; Brooks, Patrick Terrence; Boldsen, Jens Kjaergaard; Mikkelsen, Christina; Gybel-Brask, Mikkel; Sørensen, Erik; Dinh, Khoa Manh; Mikkelsen, Susan; Moller, Bjarne Kuno; Haunstrup, Thure; Harritshøj, Lene; Jensen, Bitten Aagaard; Hjalgrim, Henrik; Lillevang, Søren Thue; Ullum, Henrik.

In: Clinical Infectious Diseases, Vol. 72, No. 2, 2021, p. 249-253.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Erikstrup, C, Hother, CE, Pedersen, OBV, Mølbak, K, Skov, RL, Holm, DK, Saekmose, SG, Nilsson, AC, Brooks, PT, Boldsen, JK, Mikkelsen, C, Gybel-Brask, M, Sørensen, E, Dinh, KM, Mikkelsen, S, Moller, BK, Haunstrup, T, Harritshøj, L, Jensen, BA, Hjalgrim, H, Lillevang, ST & Ullum, H 2021, 'Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors', Clinical Infectious Diseases, vol. 72, no. 2, pp. 249-253. https://doi.org/10.1093/cid/ciaa849

APA

Erikstrup, C., Hother, C. E., Pedersen, O. B. V., Mølbak, K., Skov, R. L., Holm, D. K., Saekmose, S. G., Nilsson, A. C., Brooks, P. T., Boldsen, J. K., Mikkelsen, C., Gybel-Brask, M., Sørensen, E., Dinh, K. M., Mikkelsen, S., Moller, B. K., Haunstrup, T., Harritshøj, L., Jensen, B. A., ... Ullum, H. (2021). Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors. Clinical Infectious Diseases, 72(2), 249-253. https://doi.org/10.1093/cid/ciaa849

Vancouver

Erikstrup C, Hother CE, Pedersen OBV, Mølbak K, Skov RL, Holm DK et al. Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors. Clinical Infectious Diseases. 2021;72(2):249-253. https://doi.org/10.1093/cid/ciaa849

Author

Erikstrup, Christian ; Hother, Christoffer Egeberg ; Pedersen, Ole Birger Vestager ; Mølbak, Kåre ; Skov, Robert Leo ; Holm, Dorte Kinggaard ; Saekmose, Susanne Gjorup ; Nilsson, Anna Christine ; Brooks, Patrick Terrence ; Boldsen, Jens Kjaergaard ; Mikkelsen, Christina ; Gybel-Brask, Mikkel ; Sørensen, Erik ; Dinh, Khoa Manh ; Mikkelsen, Susan ; Moller, Bjarne Kuno ; Haunstrup, Thure ; Harritshøj, Lene ; Jensen, Bitten Aagaard ; Hjalgrim, Henrik ; Lillevang, Søren Thue ; Ullum, Henrik. / Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors. In: Clinical Infectious Diseases. 2021 ; Vol. 72, No. 2. pp. 249-253.

Bibtex

@article{fe7b9a5e520746b9b4f6d6dbdfc08a25,

title = "Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors",

abstract = "Background. The pandemic due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has tremendous consequences for our societies. Knowledge of the seroprevalence of SARS-CoV-2 is needed to accurately monitor the spread of the epidemic and to calculate the infection fatality rate (IFR). These measures may help the authorities make informed decisions and adjust the current societal interventions. The objective was to perform nationwide real-time seroprevalence surveying among blood donors as a tool to estimate previous SARS-CoV-2 infections and the population-based IFR.Methods. Danish blood donors aged 17-69 years giving blood 6 April to 3 May were tested for SARS-CoV-2 immunoglobulin M and G antibodies using a commercial lateral flow test. Antibody status was compared between geographical areas, and an estimate of the IFR was calculated. Seroprevalence was adjusted for assay sensitivity and specificity taking the uncertainties of the test validation into account when reporting the 95% confidence intervals (CIs).Results. The first 20 640 blood donors were tested, and a combined adjusted seroprevalence of 1.9% (95% CI, .8-2.3) was calculated. The seroprevalence differed across areas. Using available data on fatalities and population numbers, a combined IFR in patientsConclusions. The IFR was estimated to be slightly lower than previously reported from other countries not using seroprevalence data. The IFR is likely severalfold lower than the current estimate. We have initiated real-time nationwide anti-SARS-CoV-2 seroprevalence surveying of blood donations as a tool in monitoring the epidemic.",

keywords = "SARS-CoV-2, COVID-19, emerging infectious disease, seroprevalence, epidemic monitoring",

author = "Christian Erikstrup and Hother, {Christoffer Egeberg} and Pedersen, {Ole Birger Vestager} and K{\aa}re M{\o}lbak and Skov, {Robert Leo} and Holm, {Dorte Kinggaard} and Saekmose, {Susanne Gjorup} and Nilsson, {Anna Christine} and Brooks, {Patrick Terrence} and Boldsen, {Jens Kjaergaard} and Christina Mikkelsen and Mikkel Gybel-Brask and Erik S{\o}rensen and Dinh, {Khoa Manh} and Susan Mikkelsen and Moller, {Bjarne Kuno} and Thure Haunstrup and Lene Harritsh{\o}j and Jensen, {Bitten Aagaard} and Henrik Hjalgrim and Lillevang, {S{\o}ren Thue} and Henrik Ullum",

year = "2021",

doi = "10.1093/cid/ciaa849",

language = "English",

volume = "72",

pages = "249--253",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "2",

}

RIS

TY - JOUR

T1 - Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors

AU - Erikstrup, Christian

AU - Hother, Christoffer Egeberg

AU - Pedersen, Ole Birger Vestager

AU - Mølbak, Kåre

AU - Skov, Robert Leo

AU - Holm, Dorte Kinggaard

AU - Saekmose, Susanne Gjorup

AU - Nilsson, Anna Christine

AU - Brooks, Patrick Terrence

AU - Boldsen, Jens Kjaergaard

AU - Mikkelsen, Christina

AU - Gybel-Brask, Mikkel

AU - Sørensen, Erik

AU - Dinh, Khoa Manh

AU - Mikkelsen, Susan

AU - Moller, Bjarne Kuno

AU - Haunstrup, Thure

AU - Harritshøj, Lene

AU - Jensen, Bitten Aagaard

AU - Hjalgrim, Henrik

AU - Lillevang, Søren Thue

AU - Ullum, Henrik

PY - 2021

Y1 - 2021

N2 - Background. The pandemic due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has tremendous consequences for our societies. Knowledge of the seroprevalence of SARS-CoV-2 is needed to accurately monitor the spread of the epidemic and to calculate the infection fatality rate (IFR). These measures may help the authorities make informed decisions and adjust the current societal interventions. The objective was to perform nationwide real-time seroprevalence surveying among blood donors as a tool to estimate previous SARS-CoV-2 infections and the population-based IFR.Methods. Danish blood donors aged 17-69 years giving blood 6 April to 3 May were tested for SARS-CoV-2 immunoglobulin M and G antibodies using a commercial lateral flow test. Antibody status was compared between geographical areas, and an estimate of the IFR was calculated. Seroprevalence was adjusted for assay sensitivity and specificity taking the uncertainties of the test validation into account when reporting the 95% confidence intervals (CIs).Results. The first 20 640 blood donors were tested, and a combined adjusted seroprevalence of 1.9% (95% CI, .8-2.3) was calculated. The seroprevalence differed across areas. Using available data on fatalities and population numbers, a combined IFR in patientsConclusions. The IFR was estimated to be slightly lower than previously reported from other countries not using seroprevalence data. The IFR is likely severalfold lower than the current estimate. We have initiated real-time nationwide anti-SARS-CoV-2 seroprevalence surveying of blood donations as a tool in monitoring the epidemic.

AB - Background. The pandemic due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has tremendous consequences for our societies. Knowledge of the seroprevalence of SARS-CoV-2 is needed to accurately monitor the spread of the epidemic and to calculate the infection fatality rate (IFR). These measures may help the authorities make informed decisions and adjust the current societal interventions. The objective was to perform nationwide real-time seroprevalence surveying among blood donors as a tool to estimate previous SARS-CoV-2 infections and the population-based IFR.Methods. Danish blood donors aged 17-69 years giving blood 6 April to 3 May were tested for SARS-CoV-2 immunoglobulin M and G antibodies using a commercial lateral flow test. Antibody status was compared between geographical areas, and an estimate of the IFR was calculated. Seroprevalence was adjusted for assay sensitivity and specificity taking the uncertainties of the test validation into account when reporting the 95% confidence intervals (CIs).Results. The first 20 640 blood donors were tested, and a combined adjusted seroprevalence of 1.9% (95% CI, .8-2.3) was calculated. The seroprevalence differed across areas. Using available data on fatalities and population numbers, a combined IFR in patientsConclusions. The IFR was estimated to be slightly lower than previously reported from other countries not using seroprevalence data. The IFR is likely severalfold lower than the current estimate. We have initiated real-time nationwide anti-SARS-CoV-2 seroprevalence surveying of blood donations as a tool in monitoring the epidemic.

KW - SARS-CoV-2

KW - COVID-19

KW - emerging infectious disease

KW - seroprevalence

KW - epidemic monitoring

U2 - 10.1093/cid/ciaa849

DO - 10.1093/cid/ciaa849

M3 - Journal article

C2 - 33501969

VL - 72

SP - 249

EP - 253

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 2

ER -

ID: 261514349